A · Agilent Technologies, Inc.
$136.012026-07-21Sector: Healthcare; Industry: Medical - Diagnostics & Research; Sub-Industry: Life Sciences Tools & Services
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$67
-51.1% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($52 · $88) Analysts Range ($140 · $165) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2024.Q2 | $6.8B | — | 20.7% | 6.5% | $1.3B | −$104MM | $1.2B | 9.3% | — | 15.4% | $8.6B | $4.37 | — |
| 2025.Q1 | $6.5B | -4.7% | 24.0% | 15.2% | $1.3B | −$992MM | $331MM | 10.6% | — | 14.7% | $9.4B | $4.54 | — |
| 2025.Q2 | $6.5B | 0.0% | 24.0% | 15.0% | $1.3B | −$1.1B | $273MM | 10.0% | — | 14.0% | $9.6B | $4.54 | — |
| 2026.Q1 | $6.9B | 6.7% | 22.3% | 9.9% | $1.4B | −$509MM | $888MM | 10.2% | — | 14.3% | $9.9B | $4.59 | — |
| 2026.Q2 | $7.2B | 4.1% | 22.6% | 10.5% | $1.5B | −$386MM | $1.1B | 9.7% | — | 14.6% | $10.1B | $4.98 | 23.7 |
| italics below = DCF projection · 10yr Rev CAGR: 5.3% |
| 2027.Q2 | $7.7B | +6.2% | 22.4% | 11.5% | $1.5B | −$725MM | $799MM | 9.6% | $729MM | 14.6% | $10.8B | $5.12 | 26.6 |
| 2028.Q2 | $8.2B | +6.2% | 23.3% | 12.4% | $1.7B | −$730MM | $933MM | 9.5% | $777MM | 14.9% | $11.5B | $5.58 | 24.4 |
| 2029.Q2 | $8.6B | +6.0% | 24.4% | 13.3% | $1.8B | −$716MM | $1.1B | 9.4% | $843MM | 15.3% | $12.2B | $6.12 | 22.2 |
| 2030.Q2 | $9.1B | +5.7% | 25.3% | 14.3% | $2.0B | −$663MM | $1.3B | 9.3% | $915MM | 15.7% | $12.9B | $6.63 | 20.5 |
| 2031.Q2 | $9.6B | +5.7% | 25.3% | 15.3% | $2.1B | −$719MM | $1.3B | 9.2% | $858MM | 15.6% | $13.6B | $6.93 | 19.6 |
|
| Term. Yr+ | $12.6B | 4.1% | 20.6% | 20.0% | $2.1B | −$823MM | $1.3B | 8.6% | $11.7B | 10.4% | — | — | — |
Active scenario IV: $67 (-51.1% vs market)